Cardiovascular Disease Risk
Disease State Hub
Featured
03/21/2024
On March 8, the FDA approved the injectable weight loss medication, semaglutide, for reducing the risk of cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with heart...
03/21/2024
03/05/2024
In this article, Michael J Bloch, MD, discusses the usage of RAS-blocking agents, slowing the progression of end-stage renal disease, and reducing cardiovascular events in patients with advanced kidney...
03/05/2024
02/28/2024
Researchers found that the current recommendations for vitamin D intake in individuals are not enough for patients to reach optimal vitamin D levels.
02/28/2024
Interactive Features
11/15/2022
Your patient is a 29-year-old woman who drinks four cups of coffee per day, and adds sweetener to each cup. She asks you if drinking black coffee would be healthier and if sweetener is detrimental to her...
11/15/2022
08/23/2022
At a recent check-up, your 28-year-old patient says she noticed a difference in their overall health since restaurants reopened after the COVID-19 lockdown in the last couple of years. She tells you she has...
08/23/2022
09/17/2021
The American Heart Association has identified 7 key risk factors that patients can improve through lifestyle changes to help achieve ideal cardiovascular (CV) health. Print out this sheet of Life's...
09/17/2021
04/08/2020
Intake of healthy fats is recommended to lower cardiovascular risk. Do you know whether the intake of trans fats is recommended?
04/08/2020
03/05/2020
Recently, aspirin use for the prevention of cardiovascular disease has been controversial. Do you know what the ACC/AHA recommend?
03/05/2020
Clinical Insights
03/05/2024
In this article, Michael J Bloch, MD, discusses the usage of RAS-blocking agents, slowing the progression of end-stage renal disease, and reducing cardiovascular events in patients with advanced kidney...
03/05/2024
02/25/2024
In this video, Michael J. Bloch, MD, reviews and discusses a recently published study on the association of menstrual cycle regularity and length with cardiovascular diseases, including how the results...
02/25/2024
02/09/2024
Michael Bloch, MD; Evan Bloch
Michael Bloch, MD; Evan Bloch
In this article, Michael Bloch, MD, and Evan Bloch discuss findings from the SELECT trial, including the use of the glucagon-like peptide 1 receptor agonist, semaglutide, to reduce the risk of major...
02/09/2024
02/08/2024
In this video, Michael J. Bloch, MD, discusses cardiovascular disease in women, including a woman's premenopausal life and its impact on cardiovascular disease risk post-menopausally and the management of...
02/08/2024
12/09/2023
Gulsen Ozen, MD, answers questions about her team’s research in the use of statins to help reduce the risk of cardiovascular disease and type 2 diabetes in individuals with rheumatoid arthritis.
12/09/2023